235 related articles for article (PubMed ID: 12640119)
1. Transcription-dependent degradation of topoisomerase I-DNA covalent complexes.
Desai SD; Zhang H; Rodriguez-Bauman A; Yang JM; Wu X; Gounder MK; Rubin EH; Liu LF
Mol Cell Biol; 2003 Apr; 23(7):2341-50. PubMed ID: 12640119
[TBL] [Abstract][Full Text] [Related]
2. The topoisomerase IIbeta circular clamp arrests transcription and signals a 26S proteasome pathway.
Xiao H; Mao Y; Desai SD; Zhou N; Ting CY; Hwang J; Liu LF
Proc Natl Acad Sci U S A; 2003 Mar; 100(6):3239-44. PubMed ID: 12629207
[TBL] [Abstract][Full Text] [Related]
3. WRN protects against topo I but not topo II inhibitors by preventing DNA break formation.
Christmann M; Tomicic MT; Gestrich C; Roos WP; Bohr VA; Kaina B
DNA Repair (Amst); 2008 Dec; 7(12):1999-2009. PubMed ID: 18805512
[TBL] [Abstract][Full Text] [Related]
4. Cullin 3 promotes proteasomal degradation of the topoisomerase I-DNA covalent complex.
Zhang HF; Tomida A; Koshimizu R; Ogiso Y; Lei S; Tsuruo T
Cancer Res; 2004 Feb; 64(3):1114-21. PubMed ID: 14871846
[TBL] [Abstract][Full Text] [Related]
5. Induction of biphasic DNA double strand breaks and activation of multiple repair protein complexes by DNA topoisomerase I drug 7-ethyl-10-hydroxy-camptothecin.
Wu J; Yin MB; Hapke G; Tóth K; Rustum YM
Mol Pharmacol; 2002 Apr; 61(4):742-8. PubMed ID: 11901212
[TBL] [Abstract][Full Text] [Related]
6. Ubiquitin/26S proteasome-mediated degradation of topoisomerase I as a resistance mechanism to camptothecin in tumor cells.
Desai SD; Li TK; Rodriguez-Bauman A; Rubin EH; Liu LF
Cancer Res; 2001 Aug; 61(15):5926-32. PubMed ID: 11479235
[TBL] [Abstract][Full Text] [Related]
7. UV light-induced degradation of RNA polymerase II is dependent on the Cockayne's syndrome A and B proteins but not p53 or MLH1.
McKay BC; Chen F; Clarke ST; Wiggin HE; Harley LM; Ljungman M
Mutat Res; 2001 Mar; 485(2):93-105. PubMed ID: 11182541
[TBL] [Abstract][Full Text] [Related]
8. Elongation by RNA polymerase II on chromatin templates requires topoisomerase activity.
Mondal N; Zhang Y; Jonsson Z; Dhar SK; Kannapiran M; Parvin JD
Nucleic Acids Res; 2003 Sep; 31(17):5016-24. PubMed ID: 12930951
[TBL] [Abstract][Full Text] [Related]
9. Camptothecin resistance is determined by the regulation of topoisomerase I degradation mediated by ubiquitin proteasome pathway.
Ando K; Shah AK; Sachdev V; Kleinstiver BP; Taylor-Parker J; Welch MM; Hu Y; Salgia R; White FM; Parvin JD; Ozonoff A; Rameh LE; Joung JK; Bharti AK
Oncotarget; 2017 Jul; 8(27):43733-43751. PubMed ID: 28415827
[TBL] [Abstract][Full Text] [Related]
10. The novel poly(ADP-Ribose) polymerase inhibitor, AG14361, sensitizes cells to topoisomerase I poisons by increasing the persistence of DNA strand breaks.
Smith LM; Willmore E; Austin CA; Curtin NJ
Clin Cancer Res; 2005 Dec; 11(23):8449-57. PubMed ID: 16322308
[TBL] [Abstract][Full Text] [Related]
11. Ubiquitin-family modifications of topoisomerase I in camptothecin-treated human breast cancer cells.
Kanagasabai R; Liu S; Salama S; Yamasaki EF; Zhang L; Greenchurch KB; Snapka RM
Biochemistry; 2009 Apr; 48(14):3176-85. PubMed ID: 19236054
[TBL] [Abstract][Full Text] [Related]
12. DNA strand-breaks induced by the topoisomerase I inhibitor camptothecin in unstimulated human white blood cells.
Daza P; Torreblanca J; García-Herdugo G; Moreno FJ
Cell Biol Int; 2002; 26(8):707-13. PubMed ID: 12175674
[TBL] [Abstract][Full Text] [Related]
13. Novel mutation of topoisomerase I in rendering cells resistant to camptothecin.
Chang JY; Liu JF; Juang SH; Liu TW; Chen LT
Cancer Res; 2002 Jul; 62(13):3716-21. PubMed ID: 12097280
[TBL] [Abstract][Full Text] [Related]
14. Differential effects of the poly (ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro.
Bowman KJ; Newell DR; Calvert AH; Curtin NJ
Br J Cancer; 2001 Jan; 84(1):106-12. PubMed ID: 11139322
[TBL] [Abstract][Full Text] [Related]
15. The role of single strand break repair pathways in cellular responses to camptothecin induced DNA damage.
Mei C; Lei L; Tan LM; Xu XJ; He BM; Luo C; Yin JY; Li X; Zhang W; Zhou HH; Liu ZQ
Biomed Pharmacother; 2020 May; 125():109875. PubMed ID: 32036211
[TBL] [Abstract][Full Text] [Related]
16. Intermittent exposure of medulloblastoma cells to topotecan produces growth inhibition equivalent to continuous exposure.
Danks MK; Pawlik CA; Whipple DO; Wolverton JS
Clin Cancer Res; 1997 Oct; 3(10):1731-8. PubMed ID: 9815557
[TBL] [Abstract][Full Text] [Related]
17. Clinical trials using irinotecan.
Houghton PJ; Santana VM
J Pediatr Hematol Oncol; 2002 Feb; 24(2):84-5. PubMed ID: 11990709
[No Abstract] [Full Text] [Related]
18. The role of the DNA mismatch repair system in the cytotoxicity of the topoisomerase inhibitors camptothecin and etoposide to human colorectal cancer cells.
Jacob S; Aguado M; Fallik D; Praz F
Cancer Res; 2001 Sep; 61(17):6555-62. PubMed ID: 11522654
[TBL] [Abstract][Full Text] [Related]
19. Camptothecin-stabilized topoisomerase I-DNA adducts cause premature termination of transcription.
Bendixen C; Thomsen B; Alsner J; Westergaard O
Biochemistry; 1990 Jun; 29(23):5613-9. PubMed ID: 1696837
[TBL] [Abstract][Full Text] [Related]
20. Degradation of topoisomerase I induced by topoisomerase I inhibitors is dependent on inhibitor structure but independent of cell death.
Fu Q; Kim SW; Chen HX; Grill S; Cheng YC
Mol Pharmacol; 1999 Apr; 55(4):677-83. PubMed ID: 10101025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
